- Trials with a EudraCT protocol (365)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
365 result(s) found for: Other Psychiatric Disorders.
Displaying page 1 of 19.
EudraCT Number: 2004-000213-19 | Sponsor Protocol Number: 99824 | Start Date*: 2005-03-08 | |||||||||||
Sponsor Name:Lundbeck SA | |||||||||||||
Full Title: Sertindole versus risperidone safety outcome study: A randomised, partially-blinded, parallel-group, active-controlled, post-marketing study | |||||||||||||
Medical condition: Schizophrenic patients most recently treated with antipsychotics other than sertindole or risperidone, requiring a new prescription for an antipsychotic, and without any contraindications for eithe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005708-17 | Sponsor Protocol Number: ELB139202-05 | Start Date*: 2006-03-27 | |||||||||||
Sponsor Name:elbion AG | |||||||||||||
Full Title: International, multicenter, randomized, double-blind, placebo controlled, two-period, cross-over study to demonstrate safety, tolerability and anxiolytic effects of 600 mg ELB139 given orally t.i.d... | |||||||||||||
Medical condition: Male and female patients with diagnosis of concurrent panic disorder according to DSM-IV, with or without agoraphobia (DSM IV 300.21 and 300.1) according to Mini International Neuropsychiatric Inte... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001017-16 | Sponsor Protocol Number: FARM9A8J83 | Start Date*: 2012-04-16 | ||||||||||||||||
Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO C. MONDINO | ||||||||||||||||||
Full Title: A randomized controlled trial of generic substitution of antiepileptic drugs | ||||||||||||||||||
Medical condition: Epilepsy or other diseases in which using: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate and valproate in mono or politerapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004460-63 | Sponsor Protocol Number: EXPO | Start Date*: 2019-07-01 | ||||||||||||||||
Sponsor Name:South London and Maudsley NHS Foundation Trust [...] | ||||||||||||||||||
Full Title: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opi... | ||||||||||||||||||
Medical condition: Opiod addiction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001523-39 | Sponsor Protocol Number: D1050300 | Start Date*: 2013-11-08 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001064-30 | Sponsor Protocol Number: ACP-103-050 | Start Date*: 2018-12-12 | ||||||||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Phase 1, Open Label, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders | ||||||||||||||||||
Medical condition: Psychiatric Disorders | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002093-34 | Sponsor Protocol Number: NW-3509/020/III/2021 | Start Date*: 2021-11-12 | |||||||||||||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS SPA | |||||||||||||||||||||||
Full Title: A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre... | |||||||||||||||||||||||
Medical condition: Patients with psychiatric disorders who participated in a previous trial with evenamide. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000256-33 | Sponsor Protocol Number: Ra-P-OCD-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement | |||||||||||||
Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000562-13 | Sponsor Protocol Number: 3151A1-309-EU | Start Date*: 2004-07-26 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development | ||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | ||
Medical condition: Major depressive disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004579-37 | Sponsor Protocol Number: MZ12-PCP-PalenicekTomas-A | Start Date*: 2014-06-18 |
Sponsor Name:National Institute of Mental Health | ||
Full Title: Animal and human serotonergic model of schizophrenia: validity evaluated by qEEG and fMRI | ||
Medical condition: Inclusion criteria: a) Men and women at age between 28 and 65 years b) healthy volunteers with negative psychiatric history (severe mental illnesses that meet the criteria of ICD 10 F0.X - F99.X) ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006486-38 | Sponsor Protocol Number: ComplexitDOC_PSI | Start Date*: 2022-08-17 |
Sponsor Name:University of Liege | ||
Full Title: Complexity-enhancing drugs to treat disorders of consciousness (DoC): a psilocybin study | ||
Medical condition: Disorders of consciousness as unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS) after a coma due to acquired brain injury. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002711-25 | Sponsor Protocol Number: 039SC04253 | Start Date*: 2005-08-01 | |||||||||||
Sponsor Name:ANGELINI | |||||||||||||
Full Title: DOSE-FINDING STUDY OF TRAZODONE IN THE TREATMENT OF PATIENTS WITH PRIMARY INSOMNIA | |||||||||||||
Medical condition: TREATMENT OF THE INSOMNIA | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004834-26 | Sponsor Protocol Number: 2017-12 | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:Albert Schweitzer hospital | |||||||||||||
Full Title: Influence of dose interval on the pharmacokinetics of both unbound and total fractions of clozapine and norclozapine in psychiatric patients in the Netherlands | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000043-74 | Sponsor Protocol Number: PNAS0122 | Start Date*: 2023-07-27 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Defining and predicting neonatal inadaptation after gestational exposure to antidepressants: longitudinal exploratory analysis of psychoneuroendocrine risk factors and complications | ||
Medical condition: major depressive disorder poor neonatal adaptation syndrome (after antidepressant use during pregnancy) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003850-26 | Sponsor Protocol Number: 31-11-284 | Start Date*: 2012-01-30 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot Compared with 6-month Retrospectiv... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003343-11 | Sponsor Protocol Number: GLP1ALCOHOL | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:Psychiatric Centre Copenhagen | |||||||||||||
Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence? | |||||||||||||
Medical condition: Alcohol dependence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006161-11 | Sponsor Protocol Number: RC31/20/0421 | Start Date*: 2021-06-23 |
Sponsor Name: Toulouse University Hospital | ||
Full Title: LONG -TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AND COMPARISON WITH AN UNTREATED COHORT OF CHILDREN WITH P... | ||
Medical condition: Prader-willi syndrome | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004984-11 | Sponsor Protocol Number: P150962J | Start Date*: 2018-07-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: "Study of maintenance of the efficacy and adverse effects of pharmacological treatments in sex offenders with paraphilia" ESPARA | |||||||||||||
Medical condition: Sexual offenders with paraphilia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022914-15 | Sponsor Protocol Number: A3051123 | Start Date*: 2012-03-01 | |||||||||||
Sponsor Name:Pfizer, S.L.U. | |||||||||||||
Full Title: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD... | |||||||||||||
Medical condition: Nicotine Addiction with the desire to quit smoking | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) DK (Completed) FI (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020185-19 | Sponsor Protocol Number: KP7242114 | Start Date*: 2011-05-30 | ||||||||||||||||
Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||
Full Title: Optimization of Treatment and Management of Schizophrenia in Europe | ||||||||||||||||||
Medical condition: Schizophrenia ICD-10 code F20 or schizophreniform disorder ICD-10 code F23.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) DK (Prematurely Ended) AT (Completed) BE (Completed) IT (Completed) BG (Completed) RO (Suspended by CA) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
